Alfresa Holdings Makes Strategic Investment in Mycenax Biotech; the Two Companies Will Each Hold 45% of the Japanese Joint Venture to Advance Biologics Manufacturing Together
Taipei, Taiwan – October 16, 2026
Mycenax Biotech (Stock Code: 4726) held a Board of Directors meeting today (November 9), at which it approved two resolutions to deepen its presence in the Japanese market. Alfresa Holdings Corporation (“AFH”, 2784.T), a leading Japanese integrated healthcare group, will subscribe for approximately NTD460 million of common shares issued by Mycenax Biotech through a private placement at NTD26 per share, at a 24% premium to today’s closing price, and is expected to hold approximately 7.9% of the company’s shares following the capital increase. AFH’s participation in the private placement at a premium reflects its confidence in Mycenax Biotech’s technical capabilities, business direction, and long-term collaboration prospects.
Alfresa is one of Japan’s foremost prescription pharmaceutical distribution and logistics companies, with annual consolidated revenue exceeding JPY 3.1 trillion and operations spanning pharmaceutical manufacturing, wholesale, and retail. AFH’s strategic investment not only strengthens the capital ties between the two parties, but is also expected to provide solid support for Mycenax Biotech’s expansion into international markets.
In addition, Mycenax Biotech will enter into share subscription agreements with AFH, Kidswell Bio, and Chiome Bioscience to jointly increase the capital of Alfenax Biologics Corp. (“Alfenax”), the Japanese joint venture, thereby establishing a four-party collaboration framework.
Mycenax Biotech previously announced plans to build a manufacturing facility for Alfenax in Akita Prefecture, Japan. Upon completion of this capital increase, Alfenax’s capital is expected to reach JPY 2.4 billion, with Mycenax Biotech and AFH each holding 45%, and Kidswell Bio and Chiome Bioscience holding 7% and 3%, respectively. As co-largest shareholders, Mycenax Biotech and AFH are demonstrating their commitment to jointly investing resources and developing Japan’s biologics manufacturing business over the long term.
The Alfenax Akita facility project has been formally awarded a policy subsidy from Japan’s Ministry of Health, Labour and Welfare, consistent with Japan’s policy direction of promoting domestic production of biosimilars and strengthening biologics manufacturing capabilities and supply chain resilience. The facility is planned to cover drug substance production as well as aseptic fill-and-finish operations and is expected to begin operations in 2030. Under the terms of the subsidy, eligible construction expenditures may receive subsidies of up to 50%.
The complementary capabilities of the four shareholders are a key strength of this collaboration platform: Chiome Bioscience contributes antibody drugs and CMC development ; Kidswell Bio brings experience in biosimilar development; Mycenax Biotech provides CDMO process development and GMP manufacturing capabilities; and AFH offers access to Japan’s pharmaceutical industry network and distribution resources. Going forward, the partners will link Taiwan’s existing R&D and manufacturing foundation with the local site in Japan, progressively establishing technical connectivity between Taiwan and Japan and a dual-site manufacturing model, thereby enhancing the stability and flexibility of the Asian biologics supply chain.
Pei-Jiun Chen, Chairperson of Mycenax Biotech, stated: “Mycenax Biotech has been active in the Japanese market for more than a decade. Starting as a CDMO service provider, we have gradually earned the trust of Japanese customers and partners through our technology, quality, and project execution capabilities. Today, we are no longer limited to providing contract development and manufacturing services; we are also able to align with Japan’s national industrial policy and work alongside a major pharmaceutical group and biotechnology companies to advance the local biologics industry. The subsidy awarded by the Ministry of Health, Labour and Welfare for the Alfenax facility project is an important milestone in this strategic transformation.”
Chairperson Chen further explained: “Following the introduction of JCR Pharmaceuticals (4552.T) as a strategic investor in 2022, AFH has now invested in Mycenax at a premium. Together, Japanese shareholders account for nearly 30% of our shareholding, reflecting the continued deepening of cooperation and trust between Mycenax and its international partners. Through the Alfenax joint venture, Mycenax Biotech combines the complementary strengths of the four shareholders in technology, development, manufacturing, and the market, and will progressively establish a dual-site operating model across Taiwan and Japan. We look forward to Mycenax Biotech and Alfenax becoming an important contributor to the Asian biologics supply chain, and to Mycenax Biotech establishing a more differentiated strategic position within the Asian CDMO industry.”
Looking ahead, Mycenax Biotech will continue to deepen its strategic collaboration in Japan, integrating technology, manufacturing, and industry resources across Taiwan and Japan to expand into the international biologics CDMO market.
About Mycenax Biotech
Mycenax Biotech positions its CDMO brand under the concept of “Big D, Strong M,” offering one-stop services for biologics from process development to GMP manufacturing, and expands into global markets through its Taiwan-based R&D and manufacturing site and international strategic collaborations.
Established: September 2001 | Paid-in Capital: NTD2.07 billion | Stock Code: 4726 | Website: www.mycenax.com
Media Contact
Li-Ru Yeh | +886-2-2655-8951 ext. 6102 | liru.yeh@mycenax.com
Alfresa Holdings Makes Strategic Investment in Mycenax Biotech; the Two Companies Will Each Hold 45% of the Japanese Joint Venture to Advance Biologics Manufacturing Together
Taipei, Taiwan – October 16, 2026
Mycenax Biotech (Stock Code: 4726) held a Board of Directors meeting today (November 9), at which it approved two resolutions to deepen its presence in the Japanese market. Alfresa Holdings Corporation (“AFH”, 2784.T), a leading Japanese integrated healthcare group, will subscribe for approximately NTD460 million of common shares issued by Mycenax Biotech through a private placement at NTD26 per share, at a 24% premium to today’s closing price, and is expected to hold approximately 7.9% of the company’s shares following the capital increase. AFH’s participation in the private placement at a premium reflects its confidence in Mycenax Biotech’s technical capabilities, business direction, and long-term collaboration prospects.
Alfresa is one of Japan’s foremost prescription pharmaceutical distribution and logistics companies, with annual consolidated revenue exceeding JPY 3.1 trillion and operations spanning pharmaceutical manufacturing, wholesale, and retail. AFH’s strategic investment not only strengthens the capital ties between the two parties, but is also expected to provide solid support for Mycenax Biotech’s expansion into international markets.
In addition, Mycenax Biotech will enter into share subscription agreements with AFH, Kidswell Bio, and Chiome Bioscience to jointly increase the capital of Alfenax Biologics Corp. (“Alfenax”), the Japanese joint venture, thereby establishing a four-party collaboration framework.
Mycenax Biotech previously announced plans to build a manufacturing facility for Alfenax in Akita Prefecture, Japan. Upon completion of this capital increase, Alfenax’s capital is expected to reach JPY 2.4 billion, with Mycenax Biotech and AFH each holding 45%, and Kidswell Bio and Chiome Bioscience holding 7% and 3%, respectively. As co-largest shareholders, Mycenax Biotech and AFH are demonstrating their commitment to jointly investing resources and developing Japan’s biologics manufacturing business over the long term.
The Alfenax Akita facility project has been formally awarded a policy subsidy from Japan’s Ministry of Health, Labour and Welfare, consistent with Japan’s policy direction of promoting domestic production of biosimilars and strengthening biologics manufacturing capabilities and supply chain resilience. The facility is planned to cover drug substance production as well as aseptic fill-and-finish operations and is expected to begin operations in 2030. Under the terms of the subsidy, eligible construction expenditures may receive subsidies of up to 50%.
The complementary capabilities of the four shareholders are a key strength of this collaboration platform: Chiome Bioscience contributes antibody drugs and CMC development ; Kidswell Bio brings experience in biosimilar development; Mycenax Biotech provides CDMO process development and GMP manufacturing capabilities; and AFH offers access to Japan’s pharmaceutical industry network and distribution resources. Going forward, the partners will link Taiwan’s existing R&D and manufacturing foundation with the local site in Japan, progressively establishing technical connectivity between Taiwan and Japan and a dual-site manufacturing model, thereby enhancing the stability and flexibility of the Asian biologics supply chain.
Pei-Jiun Chen, Chairperson of Mycenax Biotech, stated: “Mycenax Biotech has been active in the Japanese market for more than a decade. Starting as a CDMO service provider, we have gradually earned the trust of Japanese customers and partners through our technology, quality, and project execution capabilities. Today, we are no longer limited to providing contract development and manufacturing services; we are also able to align with Japan’s national industrial policy and work alongside a major pharmaceutical group and biotechnology companies to advance the local biologics industry. The subsidy awarded by the Ministry of Health, Labour and Welfare for the Alfenax facility project is an important milestone in this strategic transformation.”
Chairperson Chen further explained: “Following the introduction of JCR Pharmaceuticals (4552.T) as a strategic investor in 2022, AFH has now invested in Mycenax at a premium. Together, Japanese shareholders account for nearly 30% of our shareholding, reflecting the continued deepening of cooperation and trust between Mycenax and its international partners. Through the Alfenax joint venture, Mycenax Biotech combines the complementary strengths of the four shareholders in technology, development, manufacturing, and the market, and will progressively establish a dual-site operating model across Taiwan and Japan. We look forward to Mycenax Biotech and Alfenax becoming an important contributor to the Asian biologics supply chain, and to Mycenax Biotech establishing a more differentiated strategic position within the Asian CDMO industry.”
Looking ahead, Mycenax Biotech will continue to deepen its strategic collaboration in Japan, integrating technology, manufacturing, and industry resources across Taiwan and Japan to expand into the international biologics CDMO market.
About Mycenax Biotech
Mycenax Biotech positions its CDMO brand under the concept of “Big D, Strong M,” offering one-stop services for biologics from process development to GMP manufacturing, and expands into global markets through its Taiwan-based R&D and manufacturing site and international strategic collaborations.
Established: September 2001 | Paid-in Capital: NTD2.07 billion | Stock Code: 4726 | Website: www.mycenax.com
Media Contact
Li-Ru Yeh | +886-2-2655-8951 ext. 6102 | liru.yeh@mycenax.com
